Maze Therapeutics, Inc.
MAZE
$41.49
$4.2211.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -98.48% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -98.48% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -98.48% | -- | -- | -- |
| SG&A Expenses | 21.45% | 23.20% | 13.19% | 7.36% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.34% | 26.14% | 15.65% | 11.53% | -- |
| Operating Income | -309.41% | -298.90% | 149.49% | 158.43% | -- |
| Income Before Tax | -323.02% | -313.03% | 149.01% | 153.18% | -- |
| Income Tax Expenses | -119.00% | -132.10% | -- | -- | -- |
| Earnings from Continuing Operations | -328.36% | -318.68% | 147.93% | 152.02% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -328.36% | -318.68% | 147.93% | 152.02% | -- |
| EBIT | -309.41% | -298.90% | 149.49% | 158.43% | -- |
| EBITDA | -294.54% | -283.46% | 154.63% | 164.45% | -- |
| EPS Basic | 42.56% | -67.81% | 105.18% | 103.36% | -- |
| Normalized Basic EPS | -151.33% | -187.04% | 184.54% | 161.19% | -- |
| EPS Diluted | 70.34% | 14.48% | 79.86% | 83.38% | -- |
| Normalized Diluted EPS | -157.86% | -228.47% | 107.99% | 82.79% | -- |
| Average Basic Shares Outstanding | 1,174.32% | 725.32% | 288.86% | 4.72% | -- |
| Average Diluted Shares Outstanding | 858.45% | 519.04% | 322.68% | 38.81% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |